Inspection Readiness in Pharma: Why Data Architecture Matters
Inspection Readiness
×
Calendar Icon 8 September 2026
Clock Icon 3 min
/ Inspection Readiness

Why Inspection Readiness Is a Data Architecture Problem

Inspection readiness depends on how quickly and reliably teams can retrieve complete batch histories. This video explains why connected data and data architecture are critical to moving from manual reconstruction to instant, reliable retrieval.

About this Video

With Mareana, you can connect manufacturing and laboratory records, preserve relationships across your data, retrieve complete batch histories from a lot number, and maintain an unbroken data lineage from incoming materials through unit operations to final release.

.

What You'll Learn

Understand why traditional approaches to inspection readiness create delays and how connected data architecture can make complete batch histories easier to retrieve.

Why incomplete and disconnected batch records can create compliance risks

How manual reconstruction slows inspection responses and consumes valuable QA resources

How connected data and retrieval can provide complete batch lineage from raw materials through final release

Full Transcript

Access the complete word-for-word transcript for easy reference and accessibility.

Show Transcript
Toggle Transcript
0:00 - 0:15

Why Inspection Readiness is a Data Architecture Problem. In pharmaceutical manufacturing inspections, unrecorded work is treated as non-existent. Regulatory inspectors treat the batch records as the true reflection of operational control.

0:15 - 0:30

A batch may be manufactured perfectly, but an incomplete or disconnected batch record indicates a lack of process control. But, historical trends suggest that most companies struggle significantly with basic process discipline and real-time documentation.

 

0:30 - 0:45

If you look at 15 years of Biologics Form 483 observations, you’ll find that failure to follow standard procedures makes up 34% of citations, failure to maintain contemporaneous documentation accounts for 21%, and inadequate investigations before batch release represent another 14%.

0:45 - 1:00

Now, the question arises, why does it happen? This breakdown happens because most facilities rely on manual reconstruction. When an inspector asks for the full history of a batch, panic sets in. Teams scatter across shared network drives, disparate lab workstations, and archive binders.

1:00 - 1:15

When an inspector asks for the full history of a batch, panic sets in. Teams scatter across shared network drives, disparate lab workstations, and archive binders. Highly paid, skilled professionals waste hours and days manually piecing together fragmented records while the audit clock runs.

1:15 - 1:30

Highly paid, skilled professionals waste hours and days manually piecing together fragmented records while the audit clock runs. This live assembly under intense scrutiny creates friction, delays answers, and exposes the organisation to severe compliance risks.

1:30 - 1:45

The moment the auditor asks a follow-up question, the team must restart that entire painful search from scratch. So, how can you overcome the inefficiencies of manual reconstruction? The answer is retrieval. Retrieval functions as a direct contrast to this chaotic scramble.

1:45 - 2:00

Retrieval functions as a direct contrast to this chaotic scramble. In an environment built on retrieval, the complete batch narrative exists long before the inspector arrives. A quality lead inputs a lot number and immediately pulls an unbroken data lineage,

2:00 - 2:15

from incoming raw materials through every unit operation to final release, in minutes. The information presents complete and connected because the underlying systems preserve that relationship from the start. Zero repeat assembly is required.

2:15 - 2:30

This difference makes connected data the cornerstone of modern compliance. Unifying manufacturing and laboratory records across the organisation transforms inspection readiness from an unpredictable manual fire drill into reliable instant access. If you are ready to make transition and ensure complete inspection readiness, reach out to us. We can help.

/ ANY QUESTIONS? WE'D LOVE TO HELP

Frequently Asked Questions

Mareana has helped numerous firms in the Pharmaceutical, Chemical, Medical Device, and Industrial Manufacturing industries.

Inspection readiness is a data architecture problem because inspectors need timely access to complete and connected batch histories. When information is fragmented across systems, teams must manually reconstruct records, increasing delays and compliance risk.

Inspection readiness means having the records, data, documentation, and evidence needed to demonstrate operational and quality control readily available when requested by regulators.

Connected data preserves relationships between manufacturing, laboratory, batch, and material records. This allows teams to retrieve a complete batch narrative without manually searching across multiple systems.

Manual reconstruction requires teams to search across shared drives, laboratory workstations, paper archives, and other systems to piece together batch information. This can take hours or days and must often be repeated when inspectors ask follow-up questions.

Data retrieval is the ability to quickly access connected manufacturing information using a relevant identifier, such as a lot number. A retrieval-based approach can provide an unbroken lineage from raw materials through manufacturing operations to final release.

Data lineage connects manufacturing data back to its originating records and sources. This helps teams demonstrate how materials, processes, laboratory results, and batch decisions relate to one another during an inspection.

Contact Us

Would you like to learn more about our pharmaceutical manufacturing solutions? Fill out the form below and one of our experts will reach out to you promptly.

By submitting your details, you agree to our Privacy Policy and to receive email communications from Mareana. You may unsubscribe at any time.

Lessons from the First FDA Warning Letter on AI Misuse
/ BEFORE YOU GO

Lessons from the First FDA Warning Letter on AI Misuse

By signing up, you agree to the Privacy Policy.